Sernova (TSX: SVA) is a clinical-stage biotechnology company developing therapeutic cell technologies with a goal to deliver a ‘functional cure’ for chronic diseases, including insulin-dependent diabetes, thyroid disease and hemophilia A. Sernova has developed the Cell Pouch System(TM), an implantable, scalable, and retrievable medical device which forms a natural environment for long-term survival and function of immune-protected therapeutic cells. In Sernova’s T1D clinical program, the first three patients to complete the trial protocol have achieved insulin independence. A second patient cohort has now been initiated with interim results expected in H2, 2023. In 2022, Sernova and Evotec (NASDAQ: EVO) entered into a partnership to develop an off-the-shelf iPSC based islet replacement therapy for potentially millions of patients with diabetes. Sernova has licensed a technology from the University of Miami to cloak cells, potentially eliminating the need for immunosuppressives to protect against immune system attack. For more information, visit the company’s website at www.sernova.com.
To schedule a one-on-one meeting, please contact your ROTH MKM representative.
To view IBN’s coverage of the conference, visit https://ibn.fm/Roth2023
About IBN’s Coverage
IBN, a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the companies participating at 35th Annual Roth Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]